Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
absolute, abstract, ASC, ASU, blue, Carryforward, CMV, compounded, Conference, construct, construction, cotton, deposit, divert, EU, eventual, expenditure, FDIC, forfeited, Georiga, GHA, heavily, HTGC, identification, immunecompromised, inconsistent, indeterminate, influenza, intrinsic, IPO, IVIG, launching, length, Marietta, milestone, moving, multiplied, nonemerging, nonqualified, oral, OTCQB, overallotment, Palivizumab, pneumoniae, preceding, preliminary, Ramsey, rat, reclassified, refinance, rental, Route, Serum, shortly, simplified, sky, stretch, symbol, Topic, tranche, underwriting, uplisting
Filing tables
Filing exhibits
Related press release
ADMA similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the annual report of ADMA Biologics, Inc., a Delaware corporation (the “Company”) on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian Lenz, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| March 28, 2014 | /s/ Brian Lenz | ||
| Name: | Brian Lenz | ||
| Title: | Chief Financial Officer (Principal Financial Officer) | ||